Dimethylaminoethyl methylcarbamate | 106552-52-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Dimethylaminoethyl methylcarbamate
• 英文别名: methyl-carbamic acid-(2-dimethylamino-ethyl ester)；Methyl-carbamidsaeure-(2-dimethylamino-aethylester)；1-Dimethylamino-2-methylcarbamoyloxy-aethan；2-(dimethylamino)ethyl methylcarbamate；2-(dimethylamino)ethyl N-methylcarbamate
• CAS: 106552-52-7
• 化学式: C₆H₁₄N₂O₂
• mdl: MFCD19219563
• 分子量: 146.189
• InChiKey: ZQLSPASKNLYZKC-UHFFFAOYSA-N

物化性质

• 沸点：
  212.0±23.0 °C(Predicted)
• 密度：
  0.993±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N,N-二甲基乙醇胺 、 异氰酸甲酯 在 乙醚 作用下， 生成 Dimethylaminoethyl methylcarbamate
  参考文献：
  名称：

  Sekera et al., Chemicke Listy, 1951, vol. 45, p. 90

  摘要：

  DOI：

文献信息

• Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
  申请人：——

  公开号：US20040092508A1

  公开（公告）日：2004-05-13

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的制药组合物和用于本发明的化学物质。
• PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3
  申请人：Desai C. Manoj

  公开号：US20070244109A1

  公开（公告）日：2007-10-18

  New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

  提供了基于新的吡咯基化合物、组合物和方法，用于体外抑制糖原合成酶激酶(GSK3)的活性和治疗GSK3介导的疾病。该发明的方法、化合物和组合物可单独应用，或与其他药理活性剂联合治疗GSK3活性介导的疾病，如糖尿病、阿尔茨海默病和其他神经退行性疾病、肥胖症、动脉粥样硬化性心血管疾病、原发性高血压、多囊卵巢综合征、X综合征、缺血、创伤性脑损伤、双相情感障碍、免疫缺陷或癌症。
• Antibacterial agents
  申请人：Andersen Niels H.

  公开号：US20090247506A1

  公开（公告）日：2009-10-01

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供式I的抗菌化合物：以及其立体异构体，药学上可接受的盐，酯和前药；包括这些化合物的药物组合物；通过给予这些化合物的途径来治疗细菌感染的方法；以及制备这些化合物的过程。
• TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE
  申请人：Olsen M. Gunnar

  公开号：US20070265241A1

  公开（公告）日：2007-11-15

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的药物组合物和用于本发明的化学物质。
• ANTIBACTERIAL AGENTS
  申请人：Andersen Niels H.

  公开号：US20080269221A1

  公开（公告）日：2008-10-30

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供化学式I的抗菌化合物：以及立体异构体，药学上可接受的盐，酯和前药; 包含这些化合物的制药组合物; 通过给予这些化合物的途径治疗细菌感染的方法; 以及制备这些化合物的工艺。